Fairvalue-Calculator Fairvalue-Calculator
EN DE

DocMorris AG (ZRSEF) Fair Value & Analysis

Healthcare · US · Market cap $501M

Price$10.24
Fair Value$1.65
Upside-83.9%
Quality95/100
Evidence: Low Range $1.02 – $2.09

Analysis

DocMorris AG (ZRSEF) currently trades at $10.24, while our model-based Fair Value estimate is $1.65 — implying the stock looks roughly 83.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +376% Alibaba Health Information Technology Limited (ALBBY) -20% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +106% Clicks Group (CLCGY) +45% Sugi Holdings (SGIPF) +83%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.